DANIEL LYNCH
CIK 1177082 · Chairman · last filed 2025-07-02
DANIEL LYNCH is a Chairman who has filed 76 SEC Form 4 insider transactions across 9 companies since 2013. The most recent filing, for SWTX, was dated Jul 2, 2025. Across all open-market trades the lifetime net is −$26.4M, making them a net seller over the disclosed history. 29 SEC filings were submitted jointly with bluebird bio, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
9
76
-$26.43M
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 0 | $46.99 | $0 | -$12.42M | 11 | 2025-07-02 |
| 2seventy bio, Inc. (TSVT) Delisted | Director | 21,053 | $5.00 | $105.3K | $0 | 3 | 2023-06-15 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 398 | $4.97 | $2.0K | -$8.17M | 27 | 2021-11-17 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 127,904 | $129.46 | $16.56M | -$5.84M | 18 | 2020-06-26 |
| Translate Bio, Inc. (TBIO) Delisted | Director | — | $0.00 | — | $0 | 2 | 2020-06-17 |
| Surface Oncology, Inc. (SURF) Delisted | Director | — | $1.07 | — | $0 | 2 | 2020-06-12 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 2 | 2019-06-21 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | 161,430 | — | — | $0 | 4 | 2017-05-23 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 4 | 2016-06-22 |
Recent Filings
76 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-02 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Disp (D) | −93,004 | $0 | EDGAR |
| 2025-05-15 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +10,060 | $0 | EDGAR |
| 2025-02-24 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −47,600 | -$2.87M | EDGAR |
| 2025-02-19 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −400 | -$24.0K | EDGAR |
| 2025-02-14 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Notice (144) | −48,000 | -$2.81M | EDGAR |
| 2025-02-12 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −175,000 | -$9.53M | EDGAR |
| 2025-02-10 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Notice (144) | −175,000 | -$7.05M | EDGAR |
| 2024-05-17 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +4,095 | $0 | EDGAR |
| 2023-06-15 | 2seventy bio, Inc. (TSVT) Delisted | Grant (A) | +8,400 | $0 | EDGAR |
| 2023-05-25 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +4,648 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.